00507_FLUKA

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

3 API Suppliers, 3 USDMF, 2 NDC API, 1 Listed Suppliers

PRICE INFORMATION

API Reference Price, API Imports

DOSSIERs // Finished Dosage Formulations

1 Dossiers, 1 FDA Orange Book

RELATED EXCIPIENT COMPANIES

Suppliers, 8 Sigachi Industries, 7 Roquette, 7 Microlex e.U, 5 Gangwal Healthcare, 4 Gangwal Chemicals, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Kerry, 2 Vasa Pharmachem, 2 DFE Pharma, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 Prachin Chemical, 1 Pharmatrans-Sanaq, 1 SPI Pharma, 1 Ideal Cures Pvt Ltd

EXCIPIENTS BY APPLICATIONS

19 Fillers, Diluents & Binders, 11 Lubricants & Glidants, 10 Thickeners and Stabilizers, 10 Direct Compression, 6 Co-Processed Excipients, 6 Disintegrants & Superdisintegrants, 5 Granulation, 4 Controlled & Modified Release, 2 Chewable & Orodispersible Aids, 2 Emulsifying Agents, 2 Coating Systems & Additives, 2 Taste Masking, 1 Rheology Modifiers, 1 Film Formers & Plasticizers, 1 API Stability Enhancers

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions

8 US Medicaid Prescriptions

ANALYTICAL SOLUTION(s)

1 USP Standards, 1 Other Ref. Standards

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 1 News

Blog

Full Screen View

Wanted: OPPORTUNITIES IN THE DRUG SHORTAGE LIST - APIs urgently needed in US and Canada

Wouldnt it be wonderful if the products that are manufactured, have such great demand that, they fly off the shelves? Our assessment of the drug shortage list in U.S. and Canada provides a list of opportunities, which are an outcome of shortage of the active pharmaceutical ingredient (API). While manufacturers struggle with ideas, we list opportunities that pharmaceutical companies can capitalize upon. Not all shortages are an outcome of manufacturing delays or quality problems; the growing demand for some products (especially injections) and lack of API supply of others is something that, if addressed, can become a potential windfall for companies (Read Forbes Millions to be made onGeneric Drugs?). Old, established active ingredients, with limited supply options are usually the ones which have been driven to shortage. Utilizing the Pharma Compass database, a comprehensive list of existing and alternate supply options was prepared to assist the industry get started Product Dosage Form Active DMFs Other potential suppliers Trimipramine Maleate Capsule Sanofi-Aventis Lundbeck R. L. Fine Chem Tiopronin Tablet Okami Chemical Industry Methylphenidate HCl Tablet, capsule Cambrex,Charles City Chattem Chemicals Euticals inc Johnson Matthey Mallinckrodt Noramco inc Rhodes Technologies Inc Siegfried USA AbbVie BASF Pharma Centaur Pharmaceuticals CF Pharma Harman Finochem Janssen Pharmaceutica Macfarlan-Smith SCI Pharmtech Sun pharmaceutical Fluoxymesterone(Androxy) Tablet Cedarburg Pharmaceuticals Inc Acetohydroxamic Acid Tablet Isochem Sa Methyldopate HCl Injectable Seratec Fomepizole Injectable Apicore US LLC Cambridge Major Labs Navinta LLC Seratec Strem Chemicals Boehringer Ingelheim facilities in St. Petersberg, Virginia, while listed have been excluded from the list on account of them shutting down the facility and subsequent plans of re-starting it not materializing. Preventing drug shortages is a key focus area for the USFDA and Health Canada. For this reason, not only do the regulatory agencies have websites which lists all the shortages, but the USFDA has also developed their own mobile app to address concerns of all the stakeholders. Addressing drug shortages is smart business since it ensures product availability, affordability and assurance along with profitability for the industry.

Impressions: 3478